Jänne, P A
Smith, I
McWalter, G
Mann, H
Dougherty, B
Walker, J
Orr, M C M
Hodgson, D R
Shaw, A T
Pereira, J R
Jeannin, G
Vansteenkiste, J
Barrios, C H
Franke, F A
Crinò, L
Smith, P
Article History
Received: 14 January 2015
Revised: 14 April 2015
Accepted: 7 May 2015
First Online: 30 June 2015
Competing interests
: PAJ has received consulting fees for drug development from AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Genentech, GlaxoSmithKline, Lab Corp, Novartis, Pfizer, and Roche, and has stock ownership in Gatekeeper Pharmaceuticals. ATS has received consulting and/or advisory board fees from Ariad, Chugai, Genentech, Ignyta, Novartis, Pfizer and Roche. IS was formerly an employee of AstraZeneca. GM, HM, MCO, DH and PS are employees and shareholders of AstraZeneca. BD and JW are employees of AstraZeneca. The remaining authors declared no conflict of interest.